Numis Securities Ltd reaffirmed their buy rating on shares of Indivior PLC (LON:INDV) in a report published on Friday morning. They currently have a GBX 500 ($6.64) price target on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently issued reports on INDV. Jefferies Group LLC raised their price objective on Indivior PLC from GBX 490 ($6.51) to GBX 540 ($7.18) and gave the company a buy rating in a research report on Friday, August 11th. Royal Bank Of Canada reaffirmed an outperform rating and issued a GBX 470 ($6.25) price objective on shares of Indivior PLC in a research report on Thursday, August 3rd. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 400 ($5.31) price objective on shares of Indivior PLC in a research report on Friday, September 15th. Finally, Citigroup Inc. reaffirmed a neutral rating and issued a GBX 280 ($3.72) price objective on shares of Indivior PLC in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of GBX 400.50 ($5.32).

Shares of Indivior PLC (INDV) traded down 0.24% on Friday, reaching GBX 327.00. The company’s stock had a trading volume of 2,213,447 shares. Indivior PLC has a 1-year low of GBX 246.50 and a 1-year high of GBX 421.50. The firm’s market cap is GBX 2.36 billion. The company’s 50 day moving average is GBX 323.48 and its 200-day moving average is GBX 336.19.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.